"21-ICRAD" Nucleic NanoVaccines for Fish

水产养殖是增长最快的粮食生产部门，但它受到传染病的严重制约。病毒感染对鱼类健康和福利的影响特别大，涉及重大的经济损失，而且只有很少的疫苗可用。因此，开发新型疫苗预防鱼类病毒性疾病对水产养殖业的可持续发展至关重要。针对鱼类病毒感染的实验性DNA疫苗已经开发出来，其中一些疫苗提供了很高的保护，但它们是注射的，不容易给幼鱼注射。重要的是，一些DNA疫苗最近已经商业化，但仍然昂贵。mRNA疫苗希望很大，但它们刚刚开始在鱼类身上进行试验。在哺乳动物中，它们通常会引起强烈的反应和良好的保护。它们似乎生产速度快，而且比DNA疫苗更安全，因为它们不应该整合到宿主基因组中。在此背景下，NucNanoFish项目建议建立一个使用可生物降解纳米颗粒的核酸平台，通过肌内注射（IM）或口服/浸泡途径有效地递送疫苗，以对抗几种欧洲养殖鱼类中众所周知的病毒性疾病。我们通过每个联盟合作伙伴的尖端专业知识选择了四种不同的相关宿主-病原体模型。NucNanoFish将设计、生产和测试DNA/mRNA核酸疫苗，这些疫苗装载或不装载在安全设计的liponanopparticles （LNP）上。LNP是基于PLA/PLGA（聚乳酸/乙醇酸）核心，周围是脂质冠。我们假设它们被粘膜有效摄取或在注射部位募集抗原呈递细胞（APC）将有利于在每个相关病毒进入的入口产生保护性免疫icrad NucNanoFish - ID: 103 / 51反应。为了实现这些目标，NucNanoFish已经组建了一个由六个具有高度互补专业知识的合作伙伴组成的联盟：一个利用LNP进行抗原和mRNA的纳米递送，四组鱼类免疫病毒学家/疫苗学家和一家DNA生产的生物技术公司。

Aquaculture is the fastest growing food production sector, but it is significantly constrained by infectious diseases. Impact of viral infectionson fish health and welfare is particularly strong, involving important economic losses, and only few vaccines are available. Therefore, it is ofparamount importance to develop new vaccines to prevent fish viral diseases for the development of a sustainable aquaculture.Experimental DNA vaccines against fish viral infections have been developed, some providing high protection but they are injected andcannot be easily administered to young fish. Importantly, several DNA vaccines have been recently made commercially available but remainexpensive. mRNA vaccines hold much hope, but they are just beginning to be tested in fish. In mammals, they often induce strongresponses and good protection. They appear to be fast to produce and safer than DNA vaccines as they should not integrate into hostgenomes.In this context, the NucNanoFish project proposes to establish a nucleic acid platform using biodegradable nanoparticles for efficientdelivery of vaccines, through intra-muscular (IM) or oral/immersion routes, against to well-known viral diseases of severalEuropean farmed fish species. We have selected four different relevant host-pathogen models through cutting edge expertise of eachconsortium's partner. NucNanoFish will design, produce and test DNA/mRNA nucleic acid vaccines loaded or not onto safe-by-designLipoNanoParticles (LNP). LNP are based on a PLA/PLGA (Poly-Lactic/Glycolic Acid) core surrounded with a lipid corona. We hypothesize thattheir efficient uptake by mucosa or the recruitment of Antigen Presenting Cells (APC) at the site of injection will favour a protective immuneICRAD NucNanoFish - ID: 10 3 of 51response at the portal of entry of each relevant virus. To achieve these goals, NucNanoFish has assembled a consortium of six partners, withhighly complementary expertise: one in nanodelivery of antigen and mRNA using LNP, four groups of fish immunovirologists / vaccinologistsand a biotech company in DNA production.